Global Lung Cancer Therapeutics Market - Growth, Trends & Forecasts (2019 - 2024)

Global Lung Cancer Therapeutics Market - Growth, Trends & Forecasts (2019 - 2024)

Purchase Report

The Global Lung Therapies Market is expected to reach USD XX million by 2022 from USD XX million in 2016, at a CAGR of XX%. Lung Cancer is the lethal lung tumor portrayed by the undisciplined growth of cells in the lung tissues. Cigarette smoking is the principal risk factor for the development of lung cancer. Prolonged exposure to tobacco smoke can also cause lung cancer. The interpretation of lung cancer is confirmed by biopsy which is carried out using bronchoscopy or CT-guidance. The two different types of lung cancer are small cell lung cancer & non-small cell lung cancer. Treatment of lung cancer can be done by chemotherapy, radiotherapy, surgery, etc.


Government funding in the field of research and development of new drugs, increasing pollution due to rapid industrialization and rise in the number of smokers are some of the reasons driving the growth of the market.


Large number of players in the market and in turn large number of drugs available in the market are the major constraints faced by the market.

Market Segmentation

The lung cancer therapeutics market is segmented on the basis of Chemotherapy, Drugs, Radiotherapy (External beam radiotherapy, internal radiotherapy and Systemic radiotherapy) and Region (North America, Europe, Asia-pacific, the Middle East & Africa and South America).

Some of the key players in this market include –

Pfizer, Ventana, Roche, Genentech, Glaxosmith, Agennix and Boehringer Ingelheim are some of the major key players.

Key Deliverables

Market analysis for the market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints opportunities and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the Global Lung Therapies Market. Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.

Related Topics Global Lung Therapies Market - Growth, Trends and Forecasts (2017 - 2022)

1. Introduction                                                 

1.1 Market Definition                                     

2. Research Methodology                                                           

3. Executive Summary                                                  

4. Key Inferences                                                            

5. Market Overview                                                         

5.1 Current Market Scenario                                       

5.2 Porters Five Forces                                

5.2.1 Bargaining Power of Suppliers                           

5.2.2 Bargaining Power of Consumers                   

5.2.3 Threats of New Entrants                  

5.2.4 Threat of Substitute Product and Services                               

5.2.5 Competitive Rivalry within the Industry                      

6. Drivers, Restraints, Opportunities and Challenges Analysis (Droc)                                        

6.1 Market Drivers          

6.1.1 Government funding in the field of research and development of new drugs

6.1.2 Increasing pollution due to rapid industrialization

6.1.3 Rise in the number of smokers

6.2 Market Restraints

6.2.1 Large number of players in the market and in turn large number of drugs available in the market

6.3 Opportunities                                            

6.4 Key Challenges

7. Market Segmentation

7.1 By Chemotherapy

7.1.1 Cisplatin

7.1.2 Taxol

7.1.3 Navelbine

7.1.4 Camptosar

7.1.5 Alimta

7.2 By Radiotherapy

7.2.1 External Beam

7.2.2 Internal

7.2.3 Systemic

7.3 By Drugs

7.3.1 Abraxane

7.3.2 Avastin

7.3.3 Crizotinib

7.3.4 Docetaxel

7.3.5 Gefitinib

7.4 Segmentation by Geography                                                     

7.4.1 North America               United States Canada Mexico  

7.4.2 Europe              France Germany       United Kingdom Italy        

7. 4.2.5 Spain    

7. 4.2.6 Rest of Europe 

7. 4.3 Asia-Pacific                     China Japan India Australia South Korea Rest of Asia-Pacific         

7.4.4 Middle East and Africa                GCC South Africa Rest of Middle East and Africa    

7.4.5 South America               Brazil Argentina     Rest of South America   

8. Competitive Landscape                                                           

8.1 Mergers and Acquisition Analysis                                    

8.2 Agreements, Collaborations & Partnerships                                

8.3 New Products Launches

9. Key Players

9.1 Pfizer

9.2 Ventana

9.3 Roche

9.4 Genentech

9.5 Glaxosmith

9.6 Agennix

9.7 Boehringer

9.8 Others 

10. Future outlook of the market

Purchase Report

Our Clients Include View All

Looking to Customize Report?

Complete your payment details below

Shipping & Billing Information

Payment Information